These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35959080)

  • 1. Emphysematous Cystitis and Urinary Retention in a Male Patient With Diabetes Mellitus Type 2 Treated With Empagliflozin.
    Brock GM; Lane SM; Roosevelt TS
    AACE Clin Case Rep; 2022; 8(4):163-165. PubMed ID: 35959080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emphysematous Cystitis: A Fatal Complication of Uncontrolled Type-2 Diabetes Mellitus.
    Raval DM; Rathod VM; Patel NS; Dobariya R; Sharma B
    Cureus; 2022 Oct; 14(10):e30028. PubMed ID: 36348872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study.
    Ferwani P; Maldar A; Shah N; Chauhan P; Chadha M
    J ASEAN Fed Endocr Soc; 2022; 37(2):5-8. PubMed ID: 36578886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
    Varshney N; Billups SJ; Saseen JJ; Fixen CW
    Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of sodium-glucose cotransporter 2 inhibitor-related genital and urinary tract infections via electronic medical record-based common data model.
    Ko S; Kim H; Shinn J; Byeon SJ; Choi JH; Kim HS
    J Clin Pharm Ther; 2021 Aug; 46(4):975-983. PubMed ID: 33565150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor.
    Sugiyama S; Jinnouchi H; Hieshima K; Kurinami N; Jinnouchi K
    Cureus; 2020 Feb; 12(2):e7110. PubMed ID: 32175210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complicated urinary tract infections with diabetes mellitus.
    Kamei J; Yamamoto S
    J Infect Chemother; 2021 Aug; 27(8):1131-1136. PubMed ID: 34024733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus.
    Unnikrishnan AG; Kalra S; Purandare V; Vasnawala H
    Indian J Endocrinol Metab; 2018; 22(6):837-842. PubMed ID: 30766827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fournier's Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report.
    Nagano Y; Yakame NK; Aoki H; Yamakawa T; Kondo NI
    Drug Saf Case Rep; 2019 Oct; 6(1):11. PubMed ID: 31628552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Concomitant Emphysematous Cystitis and Clostridium difficile Colitis with Pneumoperitoneum.
    Tariq T; Farishta M; Rizvi A; Irfan FB
    Cureus; 2018 Jun; 10(6):e2897. PubMed ID: 30181931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caution advised with dapagliflozin in the setting of male urinary tract outlet obstruction.
    Hall V; Kwong J; Johnson D; Ekinci EI
    BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28536217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease.
    Sugiyama S; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T; Jinnouchi H
    J Clin Med Res; 2020 Nov; 12(11):724-733. PubMed ID: 33224374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
    Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
    Hepatol Res; 2017 Sep; 47(10):1072-1078. PubMed ID: 27925353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Case of Emphysematous Cystitis with Bladder Diverticulum].
    Kajiwara S; Matsuura H; Arase S; Hori Y; Tochigi H; Sugimura Y
    Hinyokika Kiyo; 2016 Aug; 62(8):431-3. PubMed ID: 27624111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus.
    Nakagaito M; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Circ Rep; 2019 Sep; 1(10):405-413. PubMed ID: 33693077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.